Learn more! ! if you are a bone fide Higher Education establishment and would like to learn how the piglix project may be your answer to the challenges of 'lecture room' replacement strategies, use our feedback page now to tell us about your needs and have someone contact you to explain your options and possibilities.
|Chemical structures, small molecule drugs, biotech drugs, drug targets, drug transporters, drug target sequences, drug target SNPs, drug metabolites, drug descriptions, disease associations, dosage data, food and drug interactions, adverse drug reactions, pharmacology, mechanisms of action, drug metabolism, chemical synthesis, patent and pricing data, chemical properties, nomenclature, synonyms, chemical taxonomy, drug NMR spectra, drug GC-MS spectra, drug LC-MS spectra|
|Research center||University of Alberta and The Metabolomics Innovation Centre|
|Laboratory||Dr. David Wishart|
|Primary citation||DrugBank: a comprehensive resource for in silico drug discovery and exploration.|
|Every 2 years with monthly corrections and updates|
|Curation policy||Manually curated|
The latest release of the database (version 5.0) contains 8227 drug entries including 2003 FDA-approved small molecule drugs, 221 FDA-approved biotech (protein/peptide) drugs, 93 nutraceuticals and over 6000 experimental drugs. Additionally, 4270 non-redundant protein (i.e. drug target/enzyme/transporter/carrier) sequences are linked to these drug entries.
Each DrugCard (Fig. 1) entry contains more than 200 data fields with half of the information being devoted to drug/chemical data and the other half devoted to drug target or protein data.
Four additional databases, HMDB, T3DB, SMPDB and FooDB are also part of a general suite of metabolomic/cheminformatic databases. HMDB contains equivalent information on more than 40,000 human metabolites, T3DB contains information on 3100 common toxins and environmental pollutants, SMPDB contains pathway diagrams for nearly 700 human metabolic pathways and disease pathways, while FooDB contains equivalent information on ~28,000 food components and food additives.
The first version of DrugBank was released in 2006. This early release contained relatively modest information about 841 FDA-approved small molecule drugs and 113 biotech drugs. It also included information on 2133 drug targets. The second version of DrugBank was released in 2009. This greatly expanded and improved version of the database included 1344 approved small molecule drugs and 123 biotech drugs as well as 3037 unique drug targets. Version 2.0 also included, for the first time, withdrawn drugs and illicit drugs, extensive food-drug and drug-drug interactions as well as ADMET (absorption, distribution, metabolism, excretion and toxicity) parameters. Version 3.0 was released in 2011. This version contained 1424 approved small molecule drugs and 132 biotech drugs as well as >4000 unique drug targets. Version 3.0 also included drug transporter data, drug pathway data, drug pricing, patent and manufacturing data as well as data on >5000 experimental drugs. Version 4.0 was released in 2014. This version included 1558 FDA-approved small molecule drugs, 155 biotech drugs and 4200 unique drug targets. Version 4.0 also incorporated extensive information on drug metabolites (structures and reactions), drug taxonomy, drug spectra, drug binding constants and drug synthesis information. Table 1 provides a more complete statistical summary of the history of DrugBank’s development.
Don't forget! that your welfare and that of all your friends and colleagues here is of primary concern and a distance of six feet (1.8m) minimum is required at all times.